Vertex, Inc. (NASDAQ:VERX) experienced a price target cut on November 5, 2025, with Goldman Sachs lowering its target from ...
Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback